Converging Fronts of Cancer Treatments

In this PharmTech video feature, we take a look at a few of the latest news stories about advancements and research in the oncology field.

Cancer research and treatment center planned for London

In May 2025, Aviva Capital Partners and mixed-use developer Socius announced plans for a new £1 billion (US$1.33 billion) investment to create a cancer research and treatment center in Sutton, London, with approximately 1 million square feet of state-of-the-art research and laboratory space where life sciences companies can come together with academic researchers and clinicians to push cancer research forward.

https://www.pharmtech.com/view/cancer-research-and-treatment-center-planned-for-london

Emerging treatments for cancer

Emerging modalities for cancer treatment have been advancing. Cell and gene therapies, peptides, monoclonal antibodies, antibody drug conjugates, tumor-infiltrating lymphocytes (TILs), and vaccines such as messenger RNA, as well as a variety of other treatments have developed in recent years. While Chimeric antigen receptor (CAR T)-cells have been a focus for the industry, TILs are focused on treating solid tumors, according to Jason Bock, co-founder and CEO of CTMC. “

TILs have been around for decades, especially in academic centers, and have a slightly different approach, where we take a piece of the tumor and extract the cells, the immune cells that [have] already found their way into the tumor and are presumably fighting that tumor, and then we can have methods to expand, in some ways, rejuvenate those cells to large numbers and then reinfuse those to the same patient,” says Bock. “Another really exciting aspect about TILs is that they have inherent specificity for the tumor that allows us the opportunity to further genetically engineer them for improved fitness, persistence, or durability.”

https://www.biopharminternational.com/view/emerging-treatments-for-cancer

In other news, CellCentric, a Cambridge, UK-based clinical-stage biotechnology company, is developing as a potential first-in-class oral treatment, inobrodib, for several specific types of cancer, notably multiple myeloma. The company received $120 million in Series C funding to support a Phase II/III study in May 2025.

https://www.pharmtech.com/view/cellcentric-completes-120-million-series-c-funding-round-for-multiple-myeloma-treatment-inobrodib

What’s new in radiopharmaceuticals?

Medicines Discovery Catapult (MDC), a national life sciences service dedicated to drug discovery, and Crown Bioscience, a contract research organization, announced in September 2025 that they are collaborating on an integrated translational biology platform to be used to develop radiopharmaceuticals. The collaboration will support the advancement of radiopharmaceuticals, including new isotopes and optimizing targeting agents, and will enable testing of how radiopharmaceuticals perform in the body.

https://www.pharmtech.com/view/medicines-discovery-catapult-and-crown-bioscience-create-alliance-for-radiopharmaceuticals

In August 2025, FDA published a draft guidance document titled Oncology Therapeutic Radiopharmaceuticals: Dosage Optimization During Clinical Development that was created to assist drug sponsors with identifying an optimized dosage for radiopharmaceutical therapies (for oncology indications during clinical development. The guidance addresses clinical development before submitting a marketing application for a new indication and usage.

https://www.pharmtech.com/view/fda-releases-guidance-on-oncology-therapeutic-radiopharmaceuticals

Click the video above to learn more.